Loading
LC
Lannett Co Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Chapman John C, was filed 18 Nov 2022.
Lannett Co Inc: what insiders have been doing
Lannett Co Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for Lannett Co Inc. The previous disclosure was published on 18 November 2022.
Our records for Lannett Co Inc go back to 2006, with 101 purchases and 146 sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
779
Thresholds
n/a
Buy Volume
€11M
101 ops. · all time
Sell Volume
€53M
146 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended June 2022 · cache
Income statement
RevenueUS$293.2M
Gross profitUS$28.6M10% margin
Net income-US$199.4M-68.0% margin
Last declaration on 18 November 2022
Declarations779 total
20,000 shares@ US$0.5152.8% of flowCommon StockSEC:0001209191-22-057838:0
Canonical exit: 15 Feb 2023 (T+90)
15,000 shares@ US$0.483.4% of flowCommon StockSEC:0001209191-22-056585:0
Canonical exit: 8 Feb 2023 (T+90)
100,000 shares@ US$0.4915.6% of flowCommon StockSEC:0001209191-22-056589:0
Canonical exit: 8 Feb 2023 (T+90)
31,159 shares@ US$0.4910.4% of flowCommon stockSEC:0001209191-22-050088:0
Canonical exit: 13 Dec 2022 (T+90)
950 shares@ US$0.473.0% of flowCommon StockSEC:0001209191-22-049197:0
775 shares@ US$0.471.2% of flowCommon StockSEC:0001209191-22-049201:0
8,114 shares@ US$0.583.9% of flowCommon StockSEC:0001209191-22-043690:1
3,924 shares@ US$0.581.6% of flowCommon StockSEC:0001209191-22-043695:1
19,368 shares@ US$0.582.4% of flowCommon StockSEC:0001209191-22-043693:1
5,656 shares@ US$0.583.3% of flowCommon StockSEC:0001209191-22-043694:1
10,154 shares@ US$0.583.0% of flowCommon StockSEC:0001209191-22-043692:1
9,227 shares@ US$0.582.5% of flowCommon StockSEC:0001209191-22-043693:0
3,330 shares@ US$0.586.4% of flowCommon StockSEC:0001209191-22-043690:0
1,798 shares@ US$0.586.9% of flowCommon StockSEC:0001209191-22-043695:0
3,042 shares@ US$0.587.1% of flowCommon StockSEC:0001209191-22-043694:0
5,465 shares@ US$0.5813.9% of flowCommon StockSEC:0001209191-22-043692:0
3,319 shares@ US$0.571.3% of flowCommon StockSEC:0001209191-22-043398:1
2,386 shares@ US$0.490.6% of flowCommon StockSEC:0001209191-22-043403:1
8,589 shares@ US$0.572.5% of flowCommon StockSEC:0001209191-22-043403:2
4,784 shares@ US$0.5711.0% of flowCommon StockSEC:0001209191-22-043402:0
3,013 shares@ US$0.678.2% of flowCommon StockSEC:0001209191-22-043403:0
1 shares@ US$0.670.0% of flowCommon StockSEC:0001209191-22-043398:0
7,096 shares@ US$0.5713.5% of flowCommon StockSEC:0001209191-22-043405:0
16,384 shares@ US$0.574.3% of flowCommon StockSEC:0001209191-22-043399:0
50,000 shares@ US$0.548.2% of flowCommon StockSEC:0001209191-22-029599:0
Canonical exit: 14 Aug 2022 (T+90)
25 of 779 declarations
About Lannett Co Inc
Lannett Co Inc (ticker: LCI) is a U.S.-listed pharmaceutical company traded on the NYSE/NASDAQ market in the United States. Founded in 1942, Lannett has built its business around the development, manufacturing, packaging, marketing, and distribution of generic pharmaceutical products. For investors, the company fits squarely within the specialty generics universe: a business model characterized by manufacturing complexity, regulatory oversight, pricing pressure, and a constant need to manage supply reliability and product quality.
Today, Lannett describes itself as a U.S.-based company with corporate headquarters in Trevose, Pennsylvania, and a manufacturing and business footprint across multiple U.S. sites, including Pennsylvania and Indiana. Its Seymour, Indiana facility is its largest plant and represents a key industrial asset. The company’s operational base is therefore heavily tied to domestic manufacturing and distribution in the United States, which is relevant in a sector where regulatory compliance, quality systems, and supply continuity are central to commercial success.
Read moreShow less
Lannett’s core business remains generic pharmaceuticals, and the company says it has more than 100 unique pharmaceutical product families. Its product portfolio spans multiple dosage forms, including tablets, capsules, liquids, nasal sprays, oral solutions, and other finished dosage forms. This breadth matters because generic drug manufacturing is not only about volume; it also depends on technical know-how, formulation expertise, and the ability to maintain approved manufacturing processes. Lannett also highlights ongoing development efforts and strategic partnerships, suggesting a continued focus on expanding capabilities beyond legacy products.
From a competitive standpoint, Lannett operates in a highly crowded U.S. generics market alongside larger and better-capitalized peers. In such an environment, competitive advantage is usually derived from operational discipline rather than brand power: efficient manufacturing, FDA compliance, dependable supply, and the ability to launch or maintain products in attractive therapeutic niches. Lannett’s positioning appears to reflect that reality. The company serves wholesalers, chain drug stores, mail-order pharmacies, private label distributors, managed care organizations, hospitals, and other healthcare channels, giving it broad distribution access across the U.S. pharmaceutical supply chain.
Recent company communications emphasize Lannett’s long operating history, U.S. manufacturing base, and commitment to affordable medicines and quality standards. For market participants following SEC Form 4 insider transactions, this backdrop is important: insider activity should be interpreted in the context of a specialized pharmaceutical manufacturer whose performance is shaped by product mix, regulatory execution, and the stability of its industrial footprint. Overall, Lannett is best viewed as a focused U.S. generic drug manufacturer with a long history, domestic production assets, and exposure to the competitive economics of the lower-cost pharmaceutical segment.
